Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daiki Ueno

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Nature Genetics|July 18, 2018
Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repairParker L Sulkowski, Ranjini K Sundaram, Sebastian Oeck, et al.
BMC Cancer|June 3, 2014
The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organManabu Kakizoe, Masahiro Yao, Ukihide Tateishi, et al.
Oncotarget|September 21, 2022
Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapyDaiki Ueno, Juan C Vasquez, Amrita Sule, et al.
Oncogenesis|May 31, 2020
Ovarian BDNF promotes survival, migration, and attachment of tumor precursors originated from p53 mutant fallopian tube epithelial cellsMin Kang, Kay Yi Chong, Tobias M P Hartwich, et al.
Scientific Reports|January 28, 2025
Spinal CRH facilitates the micturition reflex via the CRH2 receptor in rats with normal bladder and bladder outlet obstructionRisa Shinoki, Ryosuke Jikuya, Takuma Nirei, et al.
Cancer Chemotherapy and Pharmacology|March 24, 2017
One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survivalHiroki Ito, Keiichi Kondo, Takashi Kawahara, et al.
Cancer Chemotherapy and Pharmacology|February 22, 2018
FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinomaNoboru Nakaigawa, Keiichi Kondo, Tomohiro Kaneta, et al.
Clinical & Experimental Metastasis|March 9, 2018
Time-dependent change in relapse sites of renal cell carcinoma after curative surgeryGo Noguchi, Noboru Nakaigawa, Masataka Taguri, et al.
Iscience|July 25, 2022
Single-cell transcriptomes underscore genetically distinct tumor characteristics and microenvironment for hereditary kidney cancersRyosuke Jikuya, Koichi Murakami, Akira Nishiyama, et al.
Molecular Cancer Research : MCR|December 22, 2025
Genetically engineered human iPS cell-derived kidney organoid recapitulates an early stage of ALK fusion gene-associated renal tumorigenesisGo Noguchi, Masaya Baba, Shinji Ohtake, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Nature Genetics|July 18, 2018
Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repairParker L Sulkowski, Ranjini K Sundaram, Sebastian Oeck, et al.
BMC Cancer|June 3, 2014
The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organManabu Kakizoe, Masahiro Yao, Ukihide Tateishi, et al.
Oncotarget|September 21, 2022
Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapyDaiki Ueno, Juan C Vasquez, Amrita Sule, et al.
Oncogenesis|May 31, 2020
Ovarian BDNF promotes survival, migration, and attachment of tumor precursors originated from p53 mutant fallopian tube epithelial cellsMin Kang, Kay Yi Chong, Tobias M P Hartwich, et al.
Scientific Reports|January 28, 2025
Spinal CRH facilitates the micturition reflex via the CRH2 receptor in rats with normal bladder and bladder outlet obstructionRisa Shinoki, Ryosuke Jikuya, Takuma Nirei, et al.
Cancer Chemotherapy and Pharmacology|March 24, 2017
One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survivalHiroki Ito, Keiichi Kondo, Takashi Kawahara, et al.
Cancer Chemotherapy and Pharmacology|February 22, 2018
FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinomaNoboru Nakaigawa, Keiichi Kondo, Tomohiro Kaneta, et al.
Clinical & Experimental Metastasis|March 9, 2018
Time-dependent change in relapse sites of renal cell carcinoma after curative surgeryGo Noguchi, Noboru Nakaigawa, Masataka Taguri, et al.
Iscience|July 25, 2022
Single-cell transcriptomes underscore genetically distinct tumor characteristics and microenvironment for hereditary kidney cancersRyosuke Jikuya, Koichi Murakami, Akira Nishiyama, et al.
Molecular Cancer Research : MCR|December 22, 2025
Genetically engineered human iPS cell-derived kidney organoid recapitulates an early stage of ALK fusion gene-associated renal tumorigenesisGo Noguchi, Masaya Baba, Shinji Ohtake, et al.
Pageof 4